# EvlaBio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/evlabio

- Industry: Biotechnology
- Headquarters: Zurich, Switzerland
- Website: www.evlabio.com
- Total disclosed funding: $25M
- Latest round: Seed (Jul 2, 2025)
- Investors on record: 5

## About

Based in Switzerland, EvlaBio develops innovative therapeutic solutions for the cardiorenal space, aiming to enhance patient outcomes through advanced treatments.EvlaBio focuses on developing therapies for cardiovascular and renal conditions. Founded in 2022 in Zurich, Switzerland, the company has engaged in 1 deal to date. Their most recent funding round was a Seed round, raising EUR 21.00 mn on July 7, 2025, led by Kurma Partners, with participation from AdBio Partners, Boehringer Ingelheim Venture, High-Tech Gründerfonds, and NRW.Venture. The total amount raised by the company is EUR 21.00 mn.EvlaBio specializes in addressing unmet needs within the cardiorenal space through innovative therapeutic solutions. The company’s core product offerings focus on advanced treatments designed to improve outcomes for patients suffering from cardiovascular and renal conditions. Their products are directed towards healthcare professionals and institutions, including hospitals and clinics primarily within the European and North American markets. By collaborating with specialized healthcare providers, EvlaBio ensures that its offerings meet the specific needs of end users, ultimately fostering better health management in the cardiorenal sector.EvlaBio's revenue generation model is structured around direct partnerships with healthcare providers and institutions. The company engages in B2B transactions, supplying its therapeutic products to hospitals and healthcare facilities that integrate these solutions into their treatment protocols. Typical agreements may involve long-term supply contracts, ensuring consistent availability of their flagship products while facilitating training and support for medical staff. Revenue is derived from the sales of proprietary treatments and ongoing support services tailored to client needs, with a pricing structure reflective of the advanced nature of their products.In July 2025, EvlaBio raised EUR 21.00 mn in Seed funding to accelerate its pre-clinical studies and drug development initiatives. The company plans to further enhance its product lineup with upcoming innovations in therapeutic solutions targeting the cardiorenal sector. Additionally, EvlaBio is strategizing to expand its market presence in both European and North American regions, aiming for broader reach and accessibility of its products by the end of 2026.

## Funding rounds

- Seed, Jul 2, 2025, $25M — Boehringer Ingelheim Venture, Kurma Partners, High-Tech Gruenderfonds, AdBio Partners, NRW.Venture

## Investors

- Boehringer Ingelheim Venture (https://capitalatlas.ai/funds/boehringer-ingelheim-venture) — Seed
- Kurma Partners (https://capitalatlas.ai/funds/kurma-partners) — Seed
- High-Tech Gruenderfonds (https://capitalatlas.ai/funds/high-tech-gruenderfonds) — Seed
- AdBio Partners (https://capitalatlas.ai/funds/adbio-partners) — Seed
- NRW.Venture (https://capitalatlas.ai/funds/nrw-venture) — Seed